

ATV/r or DRV/r in Patients with CD4 <200 cells/mm³

IMEA 040 DATA Trial

ATV/r or DRV/r in Patients with CD4 <200 cells/mm³

IMEA 040 DATA: Study Design

Study Design: IMEA 040 DATA

- **Background:** Randomized, open-label, non-comparative phase 4 trial evaluating the efficacy and tolerability of atazanavir plus ritonavir or darunavir plus ritonavir, in combination with 2NRTIs, in treatment-naïve patients with advanced HIV disease
- **Inclusion Criteria (n = 120)**
 - Age ≥ 18
 - Antiretroviral-naïve patients
 - HIV RNA >1000 copies/mL
 - CD4 <200 cells/mm³
 - No resistance to study drugs
- **Treatment Arms**
 - ATV 300 mg QD + RTV 100 mg QD + 2 NRTIs*
 - DRV 800 mg QD + 100 mg QD + 2 NRTIs*

**Atazanavir + Ritonavir
+ 2 NRTIs**
(n = 59)


**Darunavir + Ritonavir
+ 2 NRTIs**
(n = 61)

* NRTI backbone: TDF-FTC (300-200 mg) unless contraindicated, then ABC-3TC (600-300 mg)

ATV/r or DRV/r in Patients with CD4 <200 cells/mm³

IMEA 040 DATA: Result

Week 48: Virologic Outcomes



*Therapeutic success: HIV RNA ≤50 copies/mL

ATV/r or DRV/r in Patients with CD4 <200 cells/mm³

IMEA 040 DATA: Conclusions

Conclusions: “Despite good adherence, neither study regimen reached the predefined objective, suggesting a need for more potent regimens for patients with advanced HIV infection.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

